STERIS (NYSE:STE) Stock Rating Lowered by Wall Street Zen

STERIS (NYSE:STEGet Free Report) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, STERIS has an average rating of “Moderate Buy” and an average price target of $275.20.

View Our Latest Research Report on STE

STERIS Trading Up 1.5%

NYSE:STE opened at $247.97 on Friday. The company has a market capitalization of $24.32 billion, a P/E ratio of 34.58 and a beta of 1.03. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. STERIS has a 12 month low of $204.90 and a 12 month high of $269.44. The firm has a fifty day simple moving average of $256.83 and a 200-day simple moving average of $250.65.

STERIS (NYSE:STEGet Free Report) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The business’s revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, equities research analysts anticipate that STERIS will post 9.08 earnings per share for the current year.

Insiders Place Their Bets

In other STERIS news, VP Julia Madsen sold 5,008 shares of STERIS stock in a transaction on Friday, November 21st. The shares were sold at an average price of $262.00, for a total value of $1,312,096.00. Following the completion of the transaction, the vice president owned 10,710 shares of the company’s stock, valued at approximately $2,806,020. The trade was a 31.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Renato Tamaro sold 5,036 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the sale, the vice president directly owned 5,695 shares in the company, valued at approximately $1,466,747.25. The trade was a 46.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 1.07% of the company’s stock.

Institutional Trading of STERIS

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of STERIS by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock valued at $3,114,882,000 after buying an additional 73,014 shares in the last quarter. State Street Corp raised its position in STERIS by 6.0% during the fourth quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock worth $1,169,957,000 after acquiring an additional 260,001 shares during the period. Geode Capital Management LLC raised its position in STERIS by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock worth $637,259,000 after acquiring an additional 14,151 shares during the period. Orbis Allan Gray Ltd lifted its holdings in STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after purchasing an additional 556,088 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of STERIS by 16.4% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock valued at $387,797,000 after purchasing an additional 221,199 shares during the period. 94.69% of the stock is owned by institutional investors and hedge funds.

About STERIS

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

Read More

Analyst Recommendations for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.